Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (Pembro) and favezelimab or vibostolimab for patients with Bacillus Calmette-Guerin (BCG)-unresponsive High-Risk (HR) Non-Muscle-Invasive Bladder Cancer (NMIBC)

被引：0
|
作者：
Gupta, S. [1 ]
Kulkarni, G. [2 ,3 ]
Necchi, A. [4 ]
Shore, N. D. [5 ]
Dave, H. [6 ]
Kapadia, E. [6 ]
Zhao, Q. [6 ]
Kamat, A. [7 ]
机构：
[1] Cleveland Clin, Dept Genitourinary Oncol, Taussig Canc Ctr, Cleveland, OH USA
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Toronto, Univ Hlth Network, Toronto, ON, Canada
[4] Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Dept Med Oncol, Milan, Italy
[5] Carolina Urol Res Ctr, Dept Oncol, Myrtle Beach, SC USA
[6] Merck & Co Inc, Dept Clin Res, Rahway, NJ USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX USA
来源：
EUROPEAN UROLOGY | 2024年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
P312
引用
收藏
页码：S433 / S433
页数：1
相关论文
共 50 条
  • [21] Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction: Phase III KEYNOTE-676 study.
    Kamat, Ashish M.
    Shore, Neal D.
    Hahn, Noah M.
    Alanee, Shaheen Riadh
    Nishiyama, Hiroyuki
    Shariat, Shahrokh F.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    Steinberg, Gary D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] Pembrolizumab for the Treatment of Patients With Bacillus Calmette-Guerin-Unresponsive, High-Risk Non-Muscle-Invasive Bladder Cancer: Over 2 Years' Follow-Up of KEYNOTE-057.
    Krieger, Laurence Eliot Miles
    Balar, Arjun Vasant
    Ashish, Kamat
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Bajorin, Dean F.
    Roumiguie, Mathieu
    Singer, Eric A.
    Grivas, Petros
    Seo, Ho Kyung
    Hiroyuki, Nishiyama
    Konety, Badrinath R.
    Zambon, Joao Paulo
    Ekta, Kapadia
    de Wit, Ronald
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 47 - 47
  • [23] The Effectiveness of Bacillus Calmette-Guerin (BCG) Maintenance Treatment in Intermediate and High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
    Kim, B.
    Ha, J.
    Park, C.
    Kim, C.
    [J]. UROLOGY, 2012, 80 (03) : S215 - S216
  • [24] Preliminary results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
    Li, Zhiyong
    He, Liru
    Li, Xiangdong
    Yao, Kai
    Liu, Yang
    Qin, Zike
    Ye, Yunlin
    Zhou, Fangjian
    Liu, Zhuowei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [25] Interim results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
    Li, Zhiyong
    He, Liru
    Yao, Kai
    Ye, Yunlin
    Li, Xiangdong
    Qin, Zike
    Han, Hui
    Zhou, Fangjian
    Liu, Zhuowei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guerin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)
    Shariat, S. F.
    Steinberg, G.
    Kamat, A. M.
    Shore, N. D.
    Alanee, S.
    Nishiyama, H.
    Nam, K.
    Godwin, J. L.
    Kapadia, E.
    Hahn, N.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S723 - S723
  • [27] Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
    Balar, Arjun, V
    Kamat, Ashish M.
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Krieger, Laurence E. M.
    Singer, Eric A.
    Bajorin, Dean F.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Li, Haojie
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara
    de Wit, Ronald
    [J]. LANCET ONCOLOGY, 2021, 22 (07): : 919 - 930
  • [28] Comparative study between mitomycin C versus Bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer
    Zaza, Mohamed Mahmoud Abdelfatah
    Salem, Tarek Abd El-Mageed
    El-Sadat, Ahmed Mohamed
    Ali, Mohammed Hassan
    [J]. UROLOGIA JOURNAL, 2024, 91 (01) : 61 - 68
  • [29] CG0070 for the treatment of non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG)
    Uchio, Edward M.
    Li, Roger
    Steinberg, Gary
    Lamm, Donald
    Kamat, Ashish
    Packiam, Vignesh
    Anderson, Paul
    Ku, Ja Hyeon
    Chisamore, Michael
    McAdory, John
    Hnat, Nataliya
    Kim, Jee-Hyun
    Grandi, Paola
    Burke, James
    [J]. CANCER SCIENCE, 2023, 114 : 1587 - 1587
  • [30] CG0070 for the treatment of non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG)
    Li, R.
    Uchio, E.
    Steinberg, G. D.
    Shore, N.
    Anderson, P. D.
    Ben, T.
    Kamat, A.
    Keel, M.
    Packiam, V.
    McAdory, J.
    Kim, J. H.
    Chisamore, M.
    Grandi, P.
    Burke, J.
    [J]. HUMAN GENE THERAPY, 2021, 32 (19-20) : A130 - A130
12345